Rgenta Receives IND Approval for Cancer Treatment

The investigational new drug (IND) application for RGT-61159, an oral small molecule RNA modulator, for the treatment of various malignancies has been approved by Rgenta Therapeutics.

The FDA clearance will enable the business to begin the therapy’s Phase Ia/Ib first-in-human clinical study.

In order to prevent the carcinogenic MYB protein from being produced, it targets RNA splicing. This inhibition may cause cancer cells that excessively express MYB to either cease proliferating or die.

Rgenta co-founder and CEO Simon Xi commented: “Clearance of our first IND application is a significant milestone in Rgenta’s mission to develop oral, small molecule RNA-targeting medicines to treat previously incurable diseases.

“We look forward to initiating clinical studies of RGT-61159 with a first-in-human Phase1a/1b clinical study in adults with ACC and CRC to potentially provide a new therapeutic option for patients with these difficult-to-treat cancers.”